Medivir announces the first cancer project derived from its in-house nucleotide platform
Business Wire - Tue Jun 30, 1:47AM CDT
Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication, a liver targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC). The project is based on the company's expertise in nucleoside and nucleotide science and is the first cancer project to emerge from its in-house discovery efforts in oncology that were announced in 2014.
Medivir reorganises R&D structure and optimises resources through a partnership with GVK BIO
M2 - Wed Jun 17, 3:45AM CDT
Medivir AB (STO:MVIRB), a research based pharmaceutical company with a research focus on infectious diseases and oncology, announced on Tuesday a reorganisation within its Discovery Research department, increasing its focus within the core areas of oncology and infectious diseases, as well as a partnership with GVK Biosciences Private Ltd. (GVK BIO) of Hyderabad in India.
Bone Metastasis Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tvrmb7/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Alethia Biotherapeutics Inc. - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - ChemoCentryx, Inc. - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - Digna Biotech, S.L. - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - R-Pharm - Sigma-Tau S.p.A. For more information visit http://www.researchandmarkets.com/research/tv...metastasis
CCXI: 8.60 (+0.19), AMGN: 154.10 (+2.79)
Medivir: Medivir's CEO increases his shareholding in the company
Business Wire - Tue May 12, 6:11AM CDT
Regulatory News:
Medivir posts profit of SEK66.7m in Q1 2015
M2 - Wed May 06, 7:04AM CDT
Medivir AB (STO: MVIR) on Tuesday reported profit after tax of SEK66.7m, or diluted EPS of SEK2.27, for the first quarter of 2015, from January 2015 to March 2015.
MVIR: ()
Medivir's Board of Directors Has Resolved to Repurchase Own Shares
Business Wire - Wed May 06, 1:58AM CDT
Regulatory News:
Medivir AB - Interim Report January - March 2015
Business Wire - Tue May 05, 3:21AM CDT
Regulatory News:
MVIR: ()
Medivir: Positive preclinical antiviral and safety profile of MIV-802 supports continued development
Business Wire - Thu Apr 23, 7:11AM CDT
Regulatory News:
Medivir: Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis
Business Wire - Thu Apr 23, 3:39AM CDT
Regulatory News:
Medivir earns €13.8M Olysio royalty in Q1
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:06AM CDT
Medivir: OLYSIO(R) sales during the first quarter 2015
Business Wire - Tue Apr 14, 7:08AM CDT
Regulatory News:
Medivir and Cancer Research Technology Collaborate to Develop New Class of Cancer Drugs
Business Wire - Mon Apr 13, 1:36AM CDT
Regulatory News:
Medivir: Annual Report 2014
Business Wire - Tue Apr 07, 1:50AM CDT
Regulatory News:
Notice of Annual General Meeting of Medivir AB (publ)
Business Wire - Wed Apr 01, 1:49AM CDT
Regulatory News:
Medivir: New Data on Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver
Business Wire - Mon Mar 16, 2:41AM CDT
Regulatory News:
Medivir Capital Markets Meeting on 26 March 2015
Business Wire - Thu Mar 12, 2:43AM CDT
Regulatory News:
Medivir: New Members of Medivir's Management Group
Business Wire - Mon Mar 02, 7:35AM CST
Regulatory News:
MVIR: ()
Medivir announces proposal for new board of directors by nomination committee ahead of AGM 2015
M2 - Thu Feb 19, 5:47AM CST
Medivir AB (OMX: MVIR), a research based pharmaceutical company with a research focus on infectious diseases and oncology, announced on Wednesday that the company's nomination committee's proposal for a new board of directors will be submitted to the 2015 Annual General Meeting.
MVIR: ()